Skip to main content

March 2016, Vol 9, Seventh Annual Payers' Guide

Drug Updates, FDA Approvals, Payers' Guide

Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma

Drug Updates, FDA Approvals, Payers' Guide

Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer

Drug Updates, FDA Approvals, Payers' Guide

Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia

Drug Updates, FDA Approvals, Payers' Guide

Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma

Lisa A. Raedler, PhD, RPh

Drug Updates, FDA Approvals, Payers' Guide

Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus

Lisa A. Raedler, PhD, RPh

1
2
3
4
5

Page 4 of 5
Results 31 - 40 of 43